324 related articles for article (PubMed ID: 23674603)
21. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
[TBL] [Abstract][Full Text] [Related]
22. Topical application of a novel ceramide derivative, K6PC-9, inhibits dust mite extract-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Kang JS; Youm JK; Jeong SK; Park BD; Yoon WK; Han MH; Lee H; Han SB; Lee K; Park SK; Lee SH; Yang KH; Moon EY; Kim HM
Int Immunopharmacol; 2007 Dec; 7(13):1589-97. PubMed ID: 17996668
[TBL] [Abstract][Full Text] [Related]
23. Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Heo JY; Cho YS; Cheon HG
Pharmazie; 2010 Dec; 65(12):906-12. PubMed ID: 21284261
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.
Inagaki N; Shiraishi N; Igeta K; Itoh T; Chikumoto T; Nagao M; Kim JF; Nagai H
Eur J Pharmacol; 2006 Sep; 546(1-3):189-96. PubMed ID: 16914137
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Purushothaman B; Arumugam P; Kulsi G; Song JM
Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
[TBL] [Abstract][Full Text] [Related]
28. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
29. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
30. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice.
Hoppmann J; Bäumer W; Galetzka C; Höfgen N; Kietzmann M; Rundfeldt C
J Pharm Pharmacol; 2005 Dec; 57(12):1609-17. PubMed ID: 16354405
[TBL] [Abstract][Full Text] [Related]
31. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
[TBL] [Abstract][Full Text] [Related]
32. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Guttman-Yassky E; Hanifin JM; Boguniewicz M; Wollenberg A; Bissonnette R; Purohit V; Kilty I; Tallman AM; Zielinski MA
Exp Dermatol; 2019 Jan; 28(1):3-10. PubMed ID: 30332502
[TBL] [Abstract][Full Text] [Related]
33. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
[TBL] [Abstract][Full Text] [Related]
34. DA-9601 suppresses 2, 4-dinitrochlorobenzene and dust mite extract-induced atopic dermatitis-like skin lesions.
Choi EJ; Lee S; Hwang JS; Im SH; Jun CD; Lee HS; Kim SH
Int Immunopharmacol; 2011 Sep; 11(9):1260-4. PubMed ID: 21511060
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice.
Kang JS; Yoon WK; Youm JK; Jeong SK; Park BD; Han MH; Lee H; Moon EY; Han SB; Lee CW; Lee K; Park SK; Yang KH; Kim HM
Exp Dermatol; 2008 Nov; 17(11):958-64. PubMed ID: 18721197
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
[TBL] [Abstract][Full Text] [Related]
37. Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Felding J; Sørensen MD; Poulsen TD; Larsen J; Andersson C; Refer P; Engell K; Ladefoged LG; Thormann T; Vinggaard AM; Hegardt P; Søhoel A; Nielsen SF
J Med Chem; 2014 Jul; 57(14):5893-903. PubMed ID: 24984230
[TBL] [Abstract][Full Text] [Related]
38. Effect of (E)-2-(3,4-dimethoxyphenyl)-4-oxo-4H-chromen-7-yl-3-(3,4-dimethoxyphenyl) acrylate on the development of atopic dermatitis-like lesions.
Kim IS; Song GY; Kim DH; Cho SH; Yun CY; Lee JS
Life Sci; 2012 Sep; 91(9-10):338-44. PubMed ID: 22871385
[TBL] [Abstract][Full Text] [Related]
39. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
[TBL] [Abstract][Full Text] [Related]
40. Topical application of Taglisodog-eum inhibits the development of experimental atopic dermatitis.
Hwang JS; Kim JE; Kim HT; Yu YB; Im SH
J Ethnopharmacol; 2013 Jan; 145(2):536-46. PubMed ID: 23211659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
